非布司他（优立通）用于痛风的长期治疗。
Febuxostat (Uloric) for chronic treatment of gout.
出版信息
Med Lett Drugs Ther. 2009 May 18;51(1312):37-8.
PMID:19448587
Abstract
Febuxostat (Uloric--Takeda), a xanthine oxidase inhibitor, has been approved by the FDA for chronic management of hyperuricemia in patients with gout. It is the first drug marketed for treatment of gout in 40 years. Febuxostat is structurally unrelated to allopurinol, the only other commercially available inhibitor of xanthine oxidase. Xanthine oxidase inhibitors decrease serum urate concentrations by decreasing urate synthesis.
摘要
非布司他（优立通——武田制药）是一种黄嘌呤氧化酶抑制剂，已获美国食品药品监督管理局批准，用于痛风患者高尿酸血症的长期管理。它是40年来首个上市用于治疗痛风的药物。非布司他在结构上与别嘌醇无关，别嘌醇是另一种唯一可商购的黄嘌呤氧化酶抑制剂。黄嘌呤氧化酶抑制剂通过减少尿酸合成来降低血清尿酸浓度。
Zotero 插件